Another Bass 2nd Chance: A Pharma Kettle Of Fish
This article was originally published in Scrip
Executive Summary
Drug makers already were anxious about the decisions coming out of the Patent Trial and Appeal Board (PTAB) of the US Patent & Trademark Office (US PTO) – which more often than not have resulted in patents being invalidated – and the steady stream of so-called inter partes review (IPR) petitions being filed by Kyle Bass, chief investment officer at Hayman Capital Management.